Form 4: Aligos Therapeutics Executive Julian A. Symons Reports Stock Option Grant

Executive Vice President and Chief Scientific Officer of Aligos Therapeutics, Julian A. Symons, reports the acquisition of stock options.

Summary

• On September 4, 2024, Julian A. Symons, Executive Vice President and Chief Scientific Officer of Aligos Therapeutics, Inc., was granted stock options to purchase 10,880 shares of common stock.
• The exercise price of the options is $11.74 per share.
• The options vest in 48 equal monthly installments starting September 4, 2024, and will be fully vested on the fourth anniversary of the Vesting Commencement Date, subject to continued service.
• Following the transaction, Symons beneficially owns 10,880 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reports a standard executive compensation practice. It's neither overwhelmingly positive nor negative.

Positives

• The granting of stock options to a key executive aligns their interests with those of the shareholders, incentivizing them to improve company performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key talent, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Gilead, Amgen, and Biogen also use stock options to incentivize their executives.
• The vesting schedule of 48 months is typical for such grants.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the executive to increase shareholder value.
• Employees may see it as a positive sign of the company's commitment to its leadership.

Key Dates